直肠肛管黑色素瘤的诊治新进展

doi:10.3760/cma.j.cn371439-20191216-00040

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (6): 377-380.doi: 10.3760/cma.j.cn371439-20191216-00040

直肠肛管黑色素瘤的诊治新进展

张睿智, 陈鑫, 张鹏, 陶凯雄()

华中科技大学同济医学院附属协和医院胃肠外科,武汉 430022

收稿日期:2019-12-16 修回日期:2020-01-09 出版日期:2020-06-08 发布日期:2020-07-22
通讯作者: 陶凯雄 E-mail:kaixiongtao@hust.edu.cn
基金资助:
国家自然科学基金(81702386);国家自然科学基金(81874184);华中科技大学自主创新研究基金(2017KFYXJJ230);华中科技大学自主创新研究基金(2017KFYXJJ256);希思科-豪森肿瘤研究基金(Y-HS2019-38)

New progress on diagnosis and treatment of anorectal malignant melanoma

Zhang Ruizhi, Chen Xin, Zhang Peng, Tao Kaixiong()

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Received:2019-12-16 Revised:2020-01-09 Online:2020-06-08 Published:2020-07-22
Contact: Tao Kaixiong E-mail:kaixiongtao@hust.edu.cn
Supported by:
National Natural Science Foundation of China(81702386);National Natural Science Foundation of China(81874184);Huazhong University of Science and Technology Independent Innovation Research Fund(2017KFYXJJ230);Huazhong University of Science and Technology Independent Innovation Research Fund(2017KFYXJJ256);Xisike-Hansoh Cancer Research Fund(Y-HS2019-38)

摘要/Abstract

摘要：

直肠肛管黑色素瘤(ARMM)是一类起源于直肠肛管区域黏膜上皮的罕见恶性肿瘤,临床表现不典型,误诊漏诊率高。根治性手术是ARMM治疗的核心手段,尽管随着对疾病了解的深入,包括靶向治疗、免疫治疗在内的多种治疗手段得以应用于ARMM,但缺少精准的临床分级分期标准指导,ARMM的整体预后依旧较差。

关键词: 黑色素瘤, 直肠, 肛管, 诊断, 治疗

Abstract:

Anorectal malignant melanoma (ARMM) is a rare malignant melanoma arising from mucosa in anorectal area. Symptoms and signs of ARMM are not specific, causing high misdiagnosis rate in this disease. Cornerstone treatment of ARMM is radical excision. Although more systematic therapy including target therapy and immunotherapy have been applied to ARMM, as the understanding of ARMM deepens. The overall prognosis of ARMM is still poor due to the lack of accurate clinical classification and staging standards.

Key words: Melanoma, Rectum, Anal canal, Diagnosis, Therapy

张睿智, 陈鑫, 张鹏, 陶凯雄. 直肠肛管黑色素瘤的诊治新进展[J]. 国际肿瘤学杂志, 2020, 47(6): 377-380.

Zhang Ruizhi, Chen Xin, Zhang Peng, Tao Kaixiong. New progress on diagnosis and treatment of anorectal malignant melanoma[J]. Journal of International Oncology, 2020, 47(6): 377-380.

参考文献 30

[1]	Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma[J]. Lancet, 2018,392(10151):971-984. DOI: 10.1016/S0140-6736(18)31559-9. doi: 10.1016/S0140-6736(18)31559-9 pmid: 30238891
[2]	Fields AC, Goldberg J, Senturk J, et al. Contemporary surgical management and outcomes for anal melanoma: a national cancer database analysis[J]. Ann Surg Oncol, 2018,25(13):3883-3888. DOI: 10.1245/s10434-018-6769-y. doi: 10.1245/s10434-018-6769-y pmid: 30209727
[3]	Naqvi J, Lee A, Lederman A, et al. Patterns of care and survival outcomes in the treatment of anal melanoma[J]. J Gastrointest Cancer, 2020,51(1):211-216. DOI: 10.1007/s12029-019-00238-5. doi: 10.1007/s12029-019-00238-5 pmid: 30982929
[4]	Ren M, Lu Y, Lv J, et al. Prognostic factors in primary anorectal melanoma: a clinicopathological study of 60 cases in China[J]. Hum Pathol, 2018,79:77-85. DOI: 10.1016/j.humpath.2018.05.004. doi: 10.1016/j.humpath.2018.05.004 pmid: 29763716
[5]	Nam S, Kim CW, Baek SJ, et al. The clinical features and optimal treatment of anorectal malignant melanoma[J]. Ann Surg Treat Res, 2014,87(3):113-117. DOI: 10.4174/astr.2014.87.3.113. doi: 10.4174/astr.2014.87.3.113
[6]	Manabe S, Boku Y, Takeda M, et al. Endoscopic submucosal dissection as excisional biopsy for anorectal malignant melanoma: a case report[J]. World J Clinl Cases, 2019,7(13):1652-1659. DOI: 10.12998/wjcc.v7.i13.1652.
[7]	Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, et al. Extracutaneous melanomas: a primer for the radiologist[J]. Insights Imaging, 2015,6(6):707-717. DOI: 10.1007/s13244-015-0427-8. doi: 10.1007/s13244-015-0427-8 pmid: 26334521
[8]	Park HJ, Kim HJ, Park SH, et al. JOURNAL CLUB: primary anorectal melanoma: MRI findings and clinicopathologic correlations[J]. AJR Am J Roentgenol, 2018,211(2):W98-W108. DOI: 10.2214/AJR.17.18807. doi: 10.2214/AJR.17.18807 pmid: 29927334
[9]	Wang S, Sun S, Liu X, et al. Endoscopic diagnosis of primary anorectal melanoma[J]. Oncotarget, 2017,8(30):50133-50140. DOI: 10.18632/oncotarget.15495. doi: 10.18632/oncotarget.15495 pmid: 28412758
[10]	Zou S, Cheng Z, Song S, et al. Anal malignant melanoma manifesting hepatic metastases shown on FDG PET/CT[J]. Clin Nucl Med, 2018,43(5):386-388. DOI: 10.1097/RLU.000000000000-2056. doi: 10.1097/RLU.0000000000002056 pmid: 29517546
[11]	Falch C, Mueller S, Kirschniak A, et al. Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with ¹⁸F-FDG-PET/CT[J]. World J Surg Oncol, 2016,14(1):185. DOI: 10.1186/s12957-016-0938-x. doi: 10.1186/s12957-016-0938-x pmid: 27422527
[12]	Valpione S, Gremel G, Mundra P, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients[J]. Eur J Cancer, 2018,88:1-9. DOI: 10.1016/j.ejca.2017.10.029. doi: 10.1016/j.ejca.2017.10.029 pmid: 29175734
[13]	Chen H, Cai Y, Liu Y, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis[J]. Medicine (Baltimore), 2016,95(7):e2770. DOI: 10.1097/MD.0000000000002770. doi: 10.1097/MD.0000000000002770
[14]	Ford MM, Kauffmann RM, Geiger TM, et al. Resection for anal melanoma: is there an optimal approach?[J]. Surgery, 2018,164(3):466-472. DOI: 10.1016/j.surg.2018.05.026. doi: 10.1016/j.surg.2018.05.026 pmid: 30041967
[15]	Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review[J]. Ann Surg, 2015,261(4):670-677. DOI: 10.1097/SLA.0000000000000862. doi: 10.1097/SLA.0000000000000862 pmid: 25119122
[16]	Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma[J]. Eur J Cance, 2014,50(1):121-127. DOI: 10.1016/j.ejca.2013.09.007.
[17]	Mignard C, Deschamps Huvier A, Gillibert A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma[J]. J Oncol, 2018,2018:1908065. DOI: 10.1155/2018/1908065. doi: 10.1155/2018/1908065 pmid: 30631354
[18]	Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma[J]. Cancer, 2016,122(21):3354-3362. DOI: 10.1002/cncr.30259. doi: 10.1002/cncr.30259 pmid: 27533633
[19]	Dodds TJ, Wilmott JS, Jackett LA, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases[J]. Pathology, 2019,51(1):39-45. DOI: 10.1016/j.pathol.2018.09.060. doi: 10.1016/j.pathol.2018.09.060 pmid: 30497801
[20]	Sakaizawa K, Ashida A, Uchiyama A, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients[J]. J Dermatol Sci, 2015,80(1):33-37. DOI: 10.1016/j.jdermsci.2015.07.012. doi: 10.1016/j.jdermsci.2015.07.012 pmid: 26282084
[21]	Gong HZ, Zheng HY, Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis[J]. Melanoma Res, 2018,28(4):259-270. DOI: 10.1097/CMR.0000000000000454. doi: 10.1097/CMR.0000000000000454 pmid: 29746316
[22]	Cinotti E, Chevallier J, Labeille B, et al. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases[J]. J Eur Acad Dermatol Venereology, 2017,31(11):1834-1840. DOI: 10.1111/jdv.14353.
[23]	Schaefer T, Satzger I, Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis of 75 patients[J]. Medicine (Baltimore), 2017,96(1):e5753. DOI: 10.1097/MD.0000000000005753. doi: 10.1097/MD.0000000000005753
[24]	Wei X, Mao L, Chi Z, et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study[J]. Oncol Res, 2019,27(4):495-501. DOI: 10.3727/096504018X-15331163433914. doi: 10.3727/096504018X15331163433914 pmid: 30075827
[25]	Buchbinder EI, Sosman JA, Lawrence DP, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma[J]. Cancer, 2015,121(22):4007-4015. DOI: 10.1002/cncr.29622. doi: 10.1002/cncr.29622 pmid: 26264378
[26]	Kalinsky K, Lee S, Rubin KM, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage Ⅳ mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)[J]. Cancer, 2017,123(14):2688-2697. DOI: 10.1002/cncr.30663. doi: 10.1002/cncr.30663 pmid: 28334439
[27]	Alrwas A, Papadopoulos NE, Cain S, et al. Phase Ⅰ trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma[J]. Melanoma Res, 2014,24(4):342-348. DOI: 10.1097/CMR.0000000000000062. doi: 10.1097/CMR.0000000000000062
[28]	Heppt MV, Roesch A, Weide B, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma[J]. Eur J Cancer, 2017,81:36-44. DOI: 10.1016/j.ejca.2017.05.014. doi: 10.1016/j.ejca.2017.05.014 pmid: 28600969
[29]	Cui C, Lian B, Zhou L, et al. Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients[J]. Ann Surg Oncol, 2018,25(8):2184-2192. DOI: 10.1245/s10434-018-6503-9. doi: 10.1245/s10434-018-6503-9 pmid: 29748886
[30]	Chae WY, Lee JL, Cho DH, et al. Preliminary suggestion about staging of anorectal malignant melanoma may be used to predict prognosis[J]. Cancer Res Treat, 2016,48(1):240-249. DOI: 10.4143/crt.2014.305. doi: 10.4143/crt.2014.305 pmid: 25761474

直肠肛管黑色素瘤的诊治新进展

New progress on diagnosis and treatment of anorectal malignant melanoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[6]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[7]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[8]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[9]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[10]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[11]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[12]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[13]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[14]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[15]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.